94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Tibau, Ariadna; Martínez, María Teresa; Ramos, Manuel; Cruz-Merino, Luis de la; Santaballa, Ana; Connor, Miriam O; Martínez-Jáñez, Noelia; Moreno, F.; Fernández-Pérez, Isaura; Virizuela, Juan Antonio; Alarcón, Jesús; Haba-Rodríguez, Juan de la; Sánchez‐Rovira, Pedro; Albacar, Cinta; Bueno, Coralia; Kelly, Cathy; Casas, Maribel; Bezares, Susana; Rosell, L.; Albanell, Joan

doi:10.1016/j.annonc.2021.03.108

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 Patients treated with fulvestrant had their QOL assessed at baseline, every 3 cycles, and at the end of treatment. 51 In combination with letrozole, palbociclib significantly improved pain scores, positively influencing the QOL. 50 However, the overall differences in HRQoL favored the group using fulvestrant and palbociclib, with reduced appetite loss.…”

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 98%

“…50 However, the overall differences in HRQoL favored the group using fulvestrant and palbociclib, with reduced appetite loss. 51…”

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 99%

“…50 However, the overall differences in HRQoL favored the group using fulvestrant and palbociclib, with reduced appetite loss. 51 One study compared the use of fulvestrant with palbociclib and abemaciclib, concluding that women with breast cancer may improve or maintain better HRQoL when using palbociclib + fulvestrant instead of abemaciclib + fulvestrant. The palbociclib group had better global QoL and emotional functioning than the abemaciclib group.…”

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 99%

See 2 more Smart Citations

Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review

Corpes

Yanez

Silva

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To map the evidence available in the literature on the health-related quality of life of women with breast cancer using hormone therapy. Data sources This review followed the Joanna Briggs Institute methodological recommendations and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting guidelines. Searches were performed in nine databases using descriptors, synonyms and keywords; grey literature was also included. The review protocol was registered with the Open Science Framework under doi: http://doi.org/10.17605/OSF.IO/347FM . Inclusion criteria were established according to the Population, Concept, and Context strategy. The selection of studies was performed by two independent reviewers with the aid of RAYYAN software and disagreements were resolved by a third reviewer. The main information from the included articles was grouped into textual categories and presented by means of a narrative synthesis. Data Summary A total of 5419 records were identified, of which 42 studies fully met the eligibility criteria. Most were multicenter studies (42.9%) and randomized controlled trials (62%). Most studies addressed anastrozole (39.5%), letrozole (34.2%), and tamoxifen (26.3%), which were studied alone or in combination. The most widely used health-related quality-of-life assessment tool was the EORTC-QLQ-C30. The concomitant use of hormone therapy and cyclin-dependent kinase inhibitors 4 and 6 showed improvement in health-related quality of life. Conclusion In recent years there has been an increase in studies focused on health-related quality of life, and the evidence pointed to relevant information on health-related quality of life and the use of endocrine therapy, tamoxifen in combination with aromatase inhibitors, as well as aromatase inhibitor alone and the use of cyclin-dependent kinase 4 and 6.

show abstract

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 98%

“…50 However, the overall differences in HRQoL favored the group using fulvestrant and palbociclib, with reduced appetite loss. 51…”

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 99%

Section: Hrqol In Women Being Treated With Hormone Therapy and Cdk 4 ...mentioning

confidence: 99%

See 1 more Smart Citation

Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review

Corpes

Yanez

Silva

et al. 2023

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib

Samjoo,

Hall,

Chen

et al. 2024

J. Comp. Eff. Res.

View full text Add to dashboard Cite

Aim: To evaluate the impact of palbociclib treatment on health-related quality of life (HRQoL) in patients with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer (HR+/HER2- aBC) or metastatic breast cancer (mBC) in both the clinical and real-world setting. Materials & methods: A systematic literature review was conducted to identify clinical trials and real-world evidence studies up to June 2023 that reported HRQoL outcomes in patients with HR+/HER2- aBC or mBC treated with Palbociclib. Results: 15 unique studies reported across 35 records were identified. Of these, seven were randomized controlled trials (RCTs), three were single-arm clinical trials and five were real-world evidence (RWE) studies. HRQoL was generally found to be maintained in patients with HR+/HER2- aBC or mBC across RCTs, single-arm clinical trials and RWE studies. HRQoL measures across instruments, study types and line of therapy, were largely reported to be at least maintained if not improved from baseline among patients treated with palbociclib and were observed to be comparable or better in the palbociclib group versus monotherapy control arm in RCTs. Similar results were seen for treatment-related outcomes (e.g., sexual functioning, upset by hair loss, systemic therapy side effects etc.), and important individual patient outcomes, including pain, fatigue and physical functioning. Findings were also consistent across key clinical characteristics (visceral metastases, neutropenia), as well as patient populations often underrepresented in clinical trials (Asian patients, older adults). Conclusion: Overall, current evidence suggests that HRQoL is largely preserved with the addition of palbociclib to endocrine therapy in patients with HR+/HER2- aBC or mBC across study types and populations.

show abstract

94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Cited by 2 publications

References 0 publications

Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review

Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review

A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib

Contact Info

Product

Resources

About